Immunotherapy is treatment that uses certain parts of a
person’s immune system to fight diseases such as cancer. This can be done in a
couple of ways, including stimulating your own immune system to work harder or
smarter to attack cancer cells or giving your immune system components, such as
man-made immune system proteins. Some types of immunotherapy are also sometimes
called biologic therapy or biotherapy. Immune Therapeutics, Inc. (OTCQB: IMUN)
is a specialty pharmaceutical company involved in the manufacture, distribution
and marketing of its novel patented therapies to combat chronic,
life-threatening diseases through the activation and modulation of the body’s
immune system. The company’s technology platform is built on two different
immunotherapies, Low Dose Naltrexone and Methionine-Enkephalin.
Stimulating the body’s immune system remains one of the most
promising approaches to addressing the unmet needs of cancers, HIV,
inflammatory disease, autoimmune disease and other chronic infectious diseases.
“If you take care of your body, then your body will take care of you.” It’s one
of the simple clichés we hear all the time from people who are usually healthy.
Your immune system is the front, middle and final line of defense against
everything your body encounters throughout your lifespan. Nurturing and
assisting the immune system with therapies like the ones mentioned above from
Immune Therapeutics make much more sense than subjecting your body to harmful
artificial treatment methodologies.
According to the Cancer.org website, nearly 14.5 million
Americans with a history of cancer were alive on January 1, 2014. About
1,685,210 new cancer cases are expected to be diagnosed in 2016, and about
595,690 Americans are expected to die from cancer in 2016, which translates to
about 1,630 people per day. Cancer is the second most common cause of death in
the U.S., exceeded only by heart disease, and it accounts for nearly one of
every four deaths. The Agency for Healthcare Research and Quality estimates
that the direct medical costs (total of all health care expenditures) for
cancer in the U.S. in 2013 were $74.8 billion.
These are startling statistics. Most families have
experienced the devastating effects of cancer firsthand. There is hope, though.
The 5-year relative survival rate for all cancers diagnosed from 2005-2011 was
69 percent, up from 49 percent from 1975-1977. Improvement in survival reflects
both the earlier diagnosis of certain cancers and improvements in treatment.
Immune Therapeutics’ treatment methodologies are a part of the next generation
in the battle against cancer and other chronic, life-threatening diseases.
Learn more by visiting www.immunetherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment